- Home
- THAR vs ALLR Comparison
THAR vs ALLR Comparison
Compare THAR & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THAR
- ALLR
- Stock Information
- Founded
- THAR 2017
- ALLR 2004
- Country
- THAR United States
- ALLR United States
- Employees
- THAR N/A
- ALLR N/A
- Industry
- THAR Biotechnology: Pharmaceutical Preparations
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- THAR Health Care
- ALLR Health Care
- Exchange
- THAR Nasdaq
- ALLR Nasdaq
- Market Cap
- THAR 22.8M
- ALLR 20.2M
- IPO Year
- THAR 2022
- ALLR N/A
- Fundamental
- Price
- THAR $3.31
- ALLR $1.22
- Analyst Decision
- THAR Strong Buy
- ALLR Strong Buy
- Analyst Count
- THAR 1
- ALLR 1
- Target Price
- THAR $17.00
- ALLR $9.25
- AVG Volume (30 Days)
- THAR 2.6M
- ALLR 292.3K
- Earning Date
- THAR 11-07-2025
- ALLR 11-14-2025
- Dividend Yield
- THAR N/A
- ALLR N/A
- EPS Growth
- THAR N/A
- ALLR N/A
- EPS
- THAR N/A
- ALLR N/A
- Revenue
- THAR N/A
- ALLR N/A
- Revenue This Year
- THAR N/A
- ALLR N/A
- Revenue Next Year
- THAR N/A
- ALLR N/A
- P/E Ratio
- THAR N/A
- ALLR N/A
- Revenue Growth
- THAR N/A
- ALLR N/A
- 52 Week Low
- THAR $0.95
- ALLR $0.61
- 52 Week High
- THAR $9.08
- ALLR $2.35
- Technical
- Relative Strength Index (RSI)
- THAR 56.35
- ALLR 35.57
- Support Level
- THAR $2.85
- ALLR $1.22
- Resistance Level
- THAR $6.89
- ALLR $1.45
- Average True Range (ATR)
- THAR 0.49
- ALLR 0.08
- MACD
- THAR 0.04
- ALLR -0.02
- Stochastic Oscillator
- THAR 14.85
- ALLR 1.59
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.